Home >> Industry News >> FDA clears FISH probes for AML, MDS

FDA clears FISH probes for AML, MDS

image_pdfCreate PDF

Feb. 11, 2019—Oxford Gene Technology has been granted de novo classification by the FDA for eight Cytocell Aquarius hematology fluorescence in situ hybridization probes for acute myeloid leukemia and myelodysplastic syndromes. The eight FISH probes tests are used to detect common chromosomal rearrangements in fixed bone marrow specimens.

CAP TODAY
X